Status:
COMPLETED
A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction
Lead Sponsor:
The Cleveland Clinic
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The objective is to obtain initial information regarding the safety and efficacy of the use of Filgrastim in the setting of acute myocardial infarction. The secondary objectives are to obtain informa...
Eligibility Criteria
Inclusion
- Acute Myocardial Infarction within 6 hours of symptoms
Exclusion
- \-
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00215124
End Date
February 1 2007
Last Update
September 19 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195